BridgeBio Pharma
BBIO
BBIO
195 hedge funds and large institutions have $2.37B invested in BridgeBio Pharma in 2021 Q4 according to their latest regulatory filings, with 37 funds opening new positions, 72 increasing their positions, 65 reducing their positions, and 51 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more ownership
Funds ownership: →
less funds holding
Funds holding: →
27% less first-time investments, than exits
New positions opened: 37 | Existing positions closed: 51
64% less capital invested
Capital invested by funds: $6.56B → $2.37B (-$4.19B)
67% less funds holding in top 10
Funds holding in top 10: 15 → 5 (-10)
Holders
195
Holding in Top 10
5
Calls
$122M
Puts
$72.8M
Top Buyers
| 1 | +$21M | |
| 2 | +$20M | |
| 3 | +$18.7M | |
| 4 |
Citigroup
New York
|
+$12.3M |
| 5 |
AIMCA
Alberta Investment Management Corp (AIMCo)
Edmonton,
Alberta, Canada
|
+$11.7M |
Top Sellers
| 1 | -$43.9M | |
| 2 | -$37.3M | |
| 3 | -$22.8M | |
| 4 |
Westfield Capital Management
Boston,
Massachusetts
|
-$22.3M |
| 5 |
Massachusetts Financial Services
Boston,
Massachusetts
|
-$20.7M |